Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

被引：30

作者：

Kaufman, Jonathan L. ^{[1
]}

Usmani, Saad Z. ^{[2
]}

San-Miguel, Jesus ^{[3
]}

Bahlis, Nizar ^{[4
]}

White, Darrell J. ^{[5
,6
]}

Benboubker, Lotfi ^{[7
]}

Cook, Gordon ^{[8
,9
]}

Leiba, Merav ^{[10
]}

Ho, P. Joy

Kim, Kihyun

Takezako, Naoki

Moreau, Philippe ^{[11
]}

Krevvata, Maria ^{[12
]}

Pei, Huiling ^{[13
]}

Ukropec, Jon ^{[14
]}

Renaud, Thomas ^{[15
]}

Trivedi, Sonali ^{[12
]}

Kobos, Rachel ^{[15
]}

Dimopoulos, Meletios A. ^{[16
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA

[3] Clin Univ Navarra CIMA, IDISNA, CIBERONC, Pamplona, Spain

[4] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[5] Dalhousie Univ, Halifax, NS, Canada

[6] QEII Hlth Sci Ctr, Halifax, NS, Canada

[7] Ctr Hosp Reg Univ CHRU, Serv Hematol & Therapie Cellulaire, Hop Bretonneau, Tours, France

[8] Teaching Hosp NHS Trust, St Jamess Inst Oncol, Leeds, W Yorkshire, England

[9] Univ Leeds, Leeds, W Yorkshire, England

[10] Ben Gurion Univ Negev, Assuta Univ Hosp, Fac Hlth Sci, Beer Sheva, Israel

[11] Univ Hosp Hotel Dieu, Hematol, Nantes, France

[12] Janssen Res & Dev LLC, Spring House, PA USA

[13] Janssen Res & Dev LLC, Titusville, NJ USA

[14] Janssen Global Med Affairs, Horsham, PA USA

[15] Janssen Res & Dev, Raritan, NJ USA

[16] Natl & Kapodistrian Univ Athens, Athens, Greece

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-123483

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1866

引用

页数：4

共 50 条

[31] ECONOMIC EVALUATION OF CARFILZOMIB plus LENALIDOMIDE plus DEXAMETHASONE (KRD) VS LENALIDOMIDE plus DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R/RMM)
Fonseca, R.
Panjabi, S.
Campioni, M.
Giannopoulou, A.
Benedict, A.
Houisse, I.
Aggarwal, S.
Jakubowiak, A.
HAEMATOLOGICA, 2016, 101 : 526 - 526
[32] Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
Dimopoulos, Meletios A.
Weisel, Katja C.
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
Miguel, Jesus San
Anderson, Kenneth Carl
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Mekan, Sabeen
Sy, Oumar
Singhal, Anil K.
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[33] Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)
Lonial, Sagar
Dimopoulos, Meletios
Weisel, Katja
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
San Miguel, Jesus
Anderson, Kenneth
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna
Beksac, Meral
Shelat, Suresh
Sy, Oumar
Singhal, Anil
Richardson, Paul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S253 - S253
[34] Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010).
Dimopoulos, MA
Spencer, A
Attal, M
Prince, M
Harousseau, JL
Dmoszynska, A
Yu, ZU
Olesnyckyj, M
Zeldis, J
Knight, R
BLOOD, 2005, 106 (11) : 6A - 7A
[35] Economic evaluation of carfilzomib plus lenalidomide plus dexamethasone (KRd) vs. lenalidomide plus dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
Jakubowiak, Andrzej J.
Benedict, Agnes
Panjabi, Sumeet
Houisse, Ivan
Campioni, Marco
Giannopoulou, Andromachi
Aggarwal, Sanjay
Fonseca, Rafael
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[36] Overall survival (OS) results with Daratumumab (DARA), Lenalidomide and Dexamethasone (D-Rd) Vs Lenalidomide and Dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM): Phase 3 MAIA study
Weisel, K.
Facon, T.
Kumar, S.
Plesner, T.
Orlowski, R. Z.
Moreau, P.
Bahlis, N.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Mace, J. R.
Raje, N.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Ahmadi, T.
Wang, J.
Rampelbergh, R., V
Uhlar, C. M.
Tromp, B.
Delioukina, M.
Vermeulen, J.
Usmani, S. Z.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 184 - 185
[37] Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial
Stewart, A. Keith
Siegel, David
Ludwig, Heinz
Facon, Thierry
Goldschmidt, Hartmut
Jakubowiak, Andrzej J.
Miguel, Jesus F. San
Obreja, Mihaela
Blaedel, Julie
Dimopoulos, Meletios A.
BLOOD, 2017, 130
[38] Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux
Moreau, Philippe
Kaufman, Jonathan L.
Sutherland, Heather J.
Lalancette, Marc
Magen, Hila
Iida, Shinsuke
Kim, Jin Seok
Prince, Miles
Cochrane, Tara
Khokhar, Nushmia Z.
Guckert, Mary
Qin, Xiang
Oriol, Albert
BLOOD, 2016, 128 (22)
[39] Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Moreau, Philippe
Bahlis, Nizar J.
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Christopher
Venner, P.
Weisel, Katja
Mace, Joseph R.
Raje, Noopur S.
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Borgsten, Fredrik
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[40] Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
Plesner, Torben
Arkenau, Hendrik-Tobias
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Laubach, Jacob P.
Palumbo, Antonio
Lisby, Steen
Basse, Linda
Wang, Jianping
Sasser, A. Kate
Guckert, Mary E.
de Boer, Carla
Khokhar, Nushmia Z.
Yeh, Howard
Clemens, Pamela L.
Ahmadi, Tahamtan
Lokhorst, Henk M.
Richardson, Paul G.
BLOOD, 2016, 128 (14) : 1821 - 1828

← 1 2 3 4 5 →